U.S. markets closed
  • S&P Futures

    3,805.50
    -11.25 (-0.29%)
     
  • Dow Futures

    31,188.00
    -48.00 (-0.15%)
     
  • Nasdaq Futures

    12,615.75
    -66.00 (-0.52%)
     
  • Russell 2000 Futures

    2,193.50
    -12.30 (-0.56%)
     
  • Crude Oil

    61.17
    -0.11 (-0.18%)
     
  • Gold

    1,709.40
    -6.40 (-0.37%)
     
  • Silver

    26.15
    -0.24 (-0.90%)
     
  • EUR/USD

    1.2055
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3935
    -0.0018 (-0.13%)
     
  • USD/JPY

    107.0360
    +0.0340 (+0.03%)
     
  • BTC-USD

    51,356.03
    +2,931.92 (+6.05%)
     
  • CMC Crypto 200

    1,026.70
    +38.60 (+3.91%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,209.05
    -350.05 (-1.18%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Astrazeneca Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 29, 2021 - AZN

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - January 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Astrazeneca Plc ("Astrazeneca") (NYSE: AZN) between May 21, 2020 and November 20, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=12484&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

If you suffered a loss in Astrazeneca you have until March 29, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73002